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Abstract 
In this study we have synthesized some Benzimidazole derivatives (2-{6-
Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) biphenyl-4-ylmethyl] 1H-
benzoimidazol-2-yl}-phenyl)-(Substituted-benzylidene)-amine and screened 
for their antihypertensive activity. 4-chloro-o-Phenylenediamine was 
condensed with anthranilic acid in presence of Polyphosphoric acid and 
different aryl aldehydes compounds with biphenyl tetrazole ring. The 
presence of specific functional group were analysed by IR spectroscopy, The 
determination of structure for the synthesized compounds by NMR and Mass 
spectroscopy 13C NMR, 1H NMR, FAB Mass.  All the synthesized 
compounds showed significant antihypertensive activity. 
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Introduction  
In recent years, attention has increasingly been given 
to the synthesis of benzimidazole derivatives as a 
source of new antimicrobial agents. The synthesis of 
novel benzimidazole derivatives remains a main focus 
of medicinal research. Recent observations suggest 
that substituted benzimidazoles and heterocycles, 
which are the structural isosters of nucleotides owing 
fused heterocyclic nuclei in their structures that allow 
them to interact easily with the biopolymers, possess 
potential activity with lower toxicities in the 
chemotherapeutic approach in man [1,2] . Moreover, 
these fused heterocylces were distinctively studied for 
their antitumor, antiviral and antimicrobial activities 
as the new nonnucleoside topoisomerase I poisons, 
human immunodeficiency virus-1 reverse 
transcriptase inhibitors and /or potent DNA gyrase 
inhibitors [3-5]. In addition, benzimidazole 
derivatives  have  played  a  crucial  role in theoretical  
development of heterocyclic chemistry and are also 
used extensively in organic synthesis. The rennin-
angiotensin system (RAS) plays a major role in the 
regulation of blood pressure and electrolyte 
homeostasis [6]. RAS is a cascade of proteolytic 
enzymes (rennin and angiotensin converting enzyme 
(ACE)) that result in the production of the systemic 
hormone angiotensin II (AII).The blockade of RAS 
with inhibitors of ACE has demonstrated the 
effectiveness of the reduction of levels of AII on 
cardiovascular and kidney heamodynamics, 
aldosterone production and release, and the 
absorption of sodium. Antagonists of AII constitute 
an alternative method blocking the RAS. Several 
peptidic and nonpeptidic AII receptor antagonists are 
known. The therapeutic availability is less for the 
peptidic AII antagonist due to their poor 
bioavailability; short plasma half-life and partial 
agonist activity but the nonpeptidic AII receptors 
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antagonist lack the defect of peptidic antagonist 
[7].The therapeutic profile of AII receptor antagonist 
is thought to be similar to that of angiotensin 
converting enzyme (ACE) inhibitors such as 
captopril, enalapril, and lisinopril. In addition, since 
AII receptor antagonist does not affect the 
metabolism of bradykinin so they may not have the 
side effect of ACE inhibitors, such as dry cough and 
angiodema. The main effects of AII are the regulation 
of blood pressure through vasoconstriction, thereby 
effecting an increase in vascular resistance, the 
regulation of volemia through the stimulated release 
of  vasopressin  and aldosterone, which induces saline  
retention, and the regulation of the 
adrenocorticotropic hormone (ACTH). Thus, 
reducing the levels of AII by inhibition of one of the 
RAS enzymes or directly blocking the AII receptors 
is in theory a good approach for treating hypertension, 
confirmed by the success of angiotensin-converting 
enzyme (ACE) inhibitors as antihypertensive [8]. 
Substantial effort has been made to find renin 
inhibitors, although orally active agents have only 
recently been reported [9].The discovery of potent 
and orally active nonpeptide Ang II antagonists such 
as losartan and eprosartan has encouraged the 
development of a large number of similar compounds 
[10-12]. 
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Figure 1. Angiotensin II selective antagonists 
 
Material and methods 
Experimental 
All melting points were taken in open capillaries and 
are uncorrected. FT-IR spectra were recorded on 
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perkin-Elmer-157 spectrophotometer instrument 
using KBr discs. 1HNMR were taken on a Bruker 
WN-400 FTMHz NMR instrument using 
DMSO/CDCl3 solvent and TMS as a internal 
standard.  
 
[MCS 01] -2-(2- aminophenyl) benzimidazole 
4-Chloro-benzene-1, 2-diamine was condensed with 
anthranilic acid in poly phosphoric acid at 168-172 0C 
for 7 hrs. The reaction mixture was poured into 
crushed ice. Filtered, washed, dried and recrystalized. 
The product 2-(2-aminophenyl) benzimidazole was 
obtained. 
 
[MCS-02] 2-(5-Nitro-1H-benzimidazole-2-yl)-
phenyl amine 
12.5 ml of concentrated nitric acid was placed in three 
necked flask and equal quantity of concentrated 
sulphuric acid (1:1) was added slowly. The mixture 
was kept in the ice cold water then compound MCS-
01 (1.5 gm) was mixed in portions during 5 hours 
under room temperature. After stirred continuously 
for 2.5 hours 15 minutes and then the reaction 
mixture was poured slowly over crushed ice with 
stirring. The precipitated product was filtered out and 
washes with cold water. The final product MCS-02 
was formed. Product was 2-(5-Nitro-1H-
benzimidazole-2-yl)-phenyl amine then treated with 
various aromatic aldehydes to obtain the Schiff bases 
compounds MCS-03. 
 
MCS-04- 4!-{2-[2-(Benzylidene-amino)-phenyl]-6-
chloro-5-nitro-benzimidazol-1-ylmethyl}-biphenyl-
2-carbonitrile 
To a solution of 1.5 g (10.12 mmol) compound aryl 
substitute -03  65 mL of DMF was added potassium 
carbonate 2.8 g (8.43 mmol), the mixture was stirred 
for 1.3 hours at room temperature, and 4-
(bromomethyl) biphenyl-2’-nitrile 5.0 g (20.12 mmol) 
was added. After stirring for 18 hours the mixture was 
poured into distilled water (120 mL) and extracted 
with diethyl ether (3 × 50 mL). The combined 
extracts were dried (MgSO4) and evaporated. 
MCS-05- (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-
yl) biphenyl-4-ylmethyl] 1H-benzoimidazol-2-yl}-
phenyl)-(Substitued-benzylidene)-amine 
A mixture of different substituted 4!-{2-[2-
(Benzylidene-amino)-phenyl]-6-chloro-5-nitro-
benzimidazol-1-ylmethyl}-biphenyl-2-carbonitrile 
(2.5 g, 3.08 mmol), sodium azide (1.21 g, 13.43 
mmol), and Et3N·HCl (2.1 g, 10.05 mmol) in NH4Cl 
(15 mL) is stirred at 160◦C for 15 hours. After 
cooling, the mixture is diluted with distilled water (50 
mL), acidified to pH 4.5with 4N HCl, and extracted 
with EtOAc (3 × 50 mL). The organic layer was 
washed with H2O (3 × 50 mL), then the combined 
extracts were dried (MgSO4) and evaporated and the 
solid residue was purified by silica gel column 
chromatography eluting with ethyl acetate/ethanol 
(80:20/v: v) to give solid Compounds. 
 
Data 
[1] (2-Chloro- benzylidene)- (2-{6-Chloro-5-nitro-
1-[2-(1H-tetrazol-5-yl) biphenyl-4-ylmethyl] 1H-
benzoimidazol-2-yl}-phenyl) - amine 
Yield:70%,m.p.=104-1060C.Mol.wt 645.0, 
Anal.Calcd forC34H22ClN8O2:C,63.26;H, 
3.44;N,17.36 %; IR (KBr): 3514-
3106,3486,1544,1621, 1543-1332 (N-O str., NO2), 
1178 (C-N str.), 815.8 (1,4 disub. Benz.Ring).  
647(C-Cl). 1HNMR (300 MHz, 
CDCl3)10.13(s,1H,tetrazole-
NH),4.97(s,2H,CH2),7.08-8.66(m,19H,ArH).13CNMR 
(CDCl3)δ:55.8, 
113.4,114.1,116.3,119.2,128.2,134.2,139.7, FAB-MS, 
646.05   
 
[2] (3-Chloro- benzylidene)-(2-{6-Chloro-5-nitro-1-
[2-(1H-tetrazol-5-yl) biphenyl-4-ylmethyl] 1H-
benzoimidazol-2-yl}-phenyl) - amine 
Yield:64%,m.p.=117-1190C.Mol.wt 645.0, 
Anal.Calcd forC34H22ClN8O2:C,63.26;H, 
3.44;N,17.36 %; IR (KBr): 3522-
3114,3489,1542,1625, 1540-1339 (N-O str., NO2), 
1175 (C-N str.), 811.0 (1,4 disub. Benz.Ring).  
651(C-Cl). 1HNMR (300 MHz, 
CDCl3)10.10(s,1H,tetrazole-
NH),4.99(s,2H,CH2),7.01-8.48(m,19H,ArH).13CNMR 
(CDCl3)δ:55.8,110.1,111.6,113.1,117.3, 
123.1,130.3,131.3,139.1, FAB-MS, 644.3   
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Figure 2. Synthesis of fifteen analogs compounds 
 
[3] (4-Chloro- benzylidene)-(2-{6-Chloro-5-nitro-1-
[2-(1H-tetrazol-5-yl) biphenyl-4-ylmethyl] 1H-
benzoimidazol-2-yl}-phenyl) – amine 
Yield:67%,m.p.=114-1160C.Mol.wt 645.0, Anal.Calcd 
forC34H22ClN8O2:C,63.26;H, 3.44;N,17.36 %; IR 
(KBr): 3517-3109,3494,1537,1613, 1546-1328 (N-O 
str., NO2), 1184 (C-N str.), 809.5 (1,4 disub. 
Benz.Ring).  650(C-Cl). 1HNMR (300 MHz, 
CDCl3)10.15(s,1H,tetrazole-NH),4.93(s,2H,CH2),6.98-
8.35(m,19H,ArH).13CNMR 
(CDCl3)δ:55.8,110.1,111.6,113.1,117.3,123.1,130.3,13
1.3,139.1,139.7,FAB-MS, 645.76  
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[4] 2-[2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H-benzoimidazol-2-yl}-
phenylimino)-methyl]phenol 
Yield:60%,m.p.=155-1580C.Mol.wt 627.0, Anal.Calcd 
forC34H23ClN8O3:C,65.12;H, 3.70;N,17.87 %; IR 
(KBr): 3548-3132,3486,3075,1527,1644, 1538-1359 
(N-O str., NO2), 1180 (C-N str.), 816.2 (1,4 disub. 
Benz.Ring).  645(C-Cl). 1HNMR (300 MHz, 
CDCl3)9.98(s,1H,tetrazole-NH),5.03(s,2H,CH2),6.98-
8.35(m,19H,ArH),5.37(arm 
OH).13CNMR(CDCl3)δ:59.2, 
112.8,113.4,116.2,117.2,126.5,130.1,132.133.8,135.1,1
36.3,136.2,139.4,140.3,142.4,FAB-MS, 626.7  
 
[5] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(2-methoxy-benzylidene)-amine 
Yield: 52%, m.p. =144-1460C.Mol.weight 641.0, 
Anal.Calcd for C35H25ClN8O3: C,65.57; H, 3.93; 
N,17.48 %. IR (KBr): 3524-3112, 3075, 2941.1 (C-H 
str.,CH3), 2895.7 (C-H str.,CH2), 1640-1518 (C=N and 
C=Cstr.), 1565-1301 (N-O str., NO2), 1178 (C-N str.), 
897.1(1,4 disub. Benz.Ring) 651.8(C-Cl). 1HNMR (300 
MHz,CDCl3)10.08(s,1H,tetrazole-NH),5.08(s,2H,CH2), 
6.98-8.35(m,19H,ArH),3.31(m,3H-OCH3). 13CNMR 
(CDCl3) δ:14.0,49, 111.3,115.1,117.8,120.2,129.2, 
139.2,149.7,FAB-MS, 641.2  
 
[6] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(3-methoxy-benzylidene)-amine 
Yield: 56%, m.p. =149-1540C.Mol.weight 641.0, 
Anal.Calcd for C35H25ClN8O3: C,65.57; H, 3.93; 
N,17.48 %. IR (KBr): 3520-3116, 3069, 2928.6 (C-H 
str.,CH3), 2898 (C-H str.,CH2), 1647-1510 (C=N and 
C=Cstr.), 1562-1314 (N-O str., NO2), 1173 (C-N str.), 
885.0(1,4 disub. Benz.Ring) 648.8(C-Cl). 1HNMR (300 
MHz, CDCl3) 10.16 (s,1H,tetrazole-NH), 5.00 
(s,2H,CH2),7.03-8.52(m,19H,ArH),3.35(m,3H-OCH3). 
13CNMR(CDCl3)δ: 17.0,51.4,110.6, 111.3,112.3,115.1, 
117.8,120.2, 129.2,139.2,143.1,FAB-MS, 640.5 
 
[7] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(4-methoxy-benzylidene)-amine 
Yield: 50%, m.p. =138-1420C.Mol.weight 641.0, 
Anal.Calcd for C35H25ClN8O3: C,65.57; H, 3.93; 
N,17.48 %. IR (KBr): 3514-3110, 2933.0 (C-H 
str.,CH3),  2884.0(C-H str.,CH2), 1645-1511 (C=N and 
C=Cstr.), 1554-1318 (N-O str., NO2), 1166 (C-N str.), 
896.3(1,4 disub. Benz.Ring) 643.5(C-Cl). 1HNMR (300 
MHz,CDCl3)10.03(s,1H,tetrazole-NH),5.05(s,2H,CH2), 
7.09-8.46(m,19H,ArH),3.37(m,3H-OCH3). 
13CNMR(CDCl3)δ:14.0,49,110.8,112.3,114.2,123.2,12
4.2,129.2,134.9,140.3,FAB-MS, 641.6 
 
[8] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(2,3-dichloro-benzylidene)-amine  
Yield: 59%, m.p. =125-1280C.Mol.weight 680.0, 
Anal.Calcd for C34H21Cl3N8O3: C,60.06; H, 3.11; 
N,16.48 %. IR (KBr): 3514-3110,  2887.3(C-H 
str.,CH2), 1640-1516 (C=N and C=Cstr.), 1538-1343 
(N-O str., NO2), 1186 (C-N str.), 890.0(1,4 disub. 
Benz.Ring) 647.6(C-Cl). 1HNMR (300 MHz, 
CDCl3)9.81(s,1H,tetrazole-NH),4.89(s,2H,CH2),7.22-
8.53(m,18H,ArH).13CNMR(CDCl3)δ:56.7,110.8,112.3,
114.1,116.8,124.2,129.2,139.5,144.2,148.7,FAB-MS, 
681.0 
 
[9] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(2,4-dichloro-benzylidene)-amine  
Yield: 64%, m.p. =131-1340C.Mol.weight 680.0, 
Anal.Calcd for C34H21Cl3N8O3: C,60.06; H, 3.11; 
N,16.48 %. IR (KBr): 3508-3126, 2887.3(C-H 
str.,CH2), 1640-1519 (C=N and C=Cstr.), 1532-1349 
(N-O str., NO2), 1180 (C-N str.), 898.0(1,4 disub. 
Benz.Ring) 649.2(C-Cl). 1HNMR (300 MHz, 
CDCl3)9.95(s,1H,tetrazole-NH),4.93(s,2H,CH2),7.17-
8.41(m,18H,ArH).13CNMR(CDCl3)δ:54.3,110.1,111.5,
117.2,124.7,127.4,133.1,138.2,FAB-MS, 679.7 
 
[10] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(2,5-dichloro-benzylidene)-amine 
Yield: 60%, m.p. =130-1330C.Mol.weight 680.0, 
Anal.Calcd for C34H21Cl3N8O3: C,60.06; H, 3.11; 
N,16.48 %. IR (KBr): 3501-3118, 2896(C-H str.,CH2), 
1647-1510 (C=N and C=Cstr.), 1530-1341 (N-O str., 
NO2), 1183 (C-N str.), 899.0(1,4 disub. Benz.Ring) 
650.7(C-Cl). 1HNMR (300 MHz, CDCl3) 
9.99(s,1H,tetrazole-NH),4.96(s,2H,CH2),7.15-8.47 
(m,18H,ArH).13CNMR(CDCl3)δ:54.3,110.1,111.5,117.
2,124.7,127.4,133.1,138.2,139.3,141.2,FAB-MS, 680.4 
 
 232
[11] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(2-nitro -benzylidene)-amine 
Yield:76%, m.p. =151-1550C.Mol.weight 656.049, 
Anal.Calcd for C34H22ClN9O4: C,62.25; H, 3.38; 
N,19.22 %. IR (KBr): 3532-3143, 2899.6 (C-H 
str.,CH2), 1647-1510 (C=N and C=Cstr.), 1566-1316 
(N-O str., NO2), 1189 (C-N str.), 891.0(1,4 disub. 
Benz.Ring) 655(C-Cl).1HNMR(300 MHz, 
CDCl3)10.25(s,1H,tetrazole-NH),5.15(s,2H,CH2),7.35-
8.67(m,19H,ArH).13CNMR(CDCl3)δ:57.6,111.4,111.8,
112.0,114.2,115.1,116.6,120.1,122.5,122.9,130.6,143.0
,FAB-MS, 655.74 
 
[12] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(3-nitro -benzylidene)-amine 
Yield:73%, m.p. =156-1590C.Mol.weight 656.049, 
Anal.Calcd for C34H22ClN9O4: C,62.25; H, 3.38; 
N,19.22 %. IR (KBr): 3538-3144, 2906.0 (C-H 
str.,CH2), 1654-1513 (C=N and C=Cstr.), 1560-1319 
(N-O str., NO2), 1195 (C-N str.), 893.6(1,4 disub. 
Benz.Ring) 659.6(C-Cl).1HNMR(300 MHz, 
CDCl3)10.20(s,1H,tetrazole-NH),5.11(s,2H,CH2),7.40-
8.53(m,19H,ArH).13CNMR(CDCl3)δ:57.6,111.4,111.8,
112.0,114.2,115.1,116.6,120.1,122.5,122.9,130.6,143.5
,143.8,FAB-MS, 656.59 
 
[13] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(4-nitro -benzylidene)-amine 
Yield:70%, m.p. =161-1640C.Mol.weight 656.049, 
Anal.Calcd for C34H22ClN9O4: C,62.25; H, 3.38; 
N,19.22 %. IR (KBr): 3535-3140, 2901.4 (C-H 
str.,CH2), 1651-1508 (C=N and C=Cstr.), 1553-1331 
(N-O str., NO2), 1187.8 (C-N str.), 895.2(1,4 disub. 
Benz.Ring) 660.5(C-Cl).1HNMR(300 MHz, 
CDCl3)10.17(s,1H,tetrazole-NH),5.10(s,2H,CH2),7.37-
8.61(m,19H,ArH).13CNMR(CDCl3)δ:57.6,111.4,111.8,
112.0,114.2,115.1,116.6,120.1,122.5,122.9,127.9,134.6
137.6,140.9,141.3,FAB-MS, 657.0 
 
[14] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(3-fluoro -benzylidene)-amine 
Yield:65%, m.p. =211-2140C.Mol.weight 629.04, 
Anal.Calcd for C34H22ClFN8O2: C,64.92; H, 3.53; 
N,17.81 %. IR (KBr): 3526-3111, 2889 (C-H str.,CH2), 
1654-1519 (C=N and C=Cstr.), 1543-1365 (N-O str., 
NO2), 1195.9 (C-N str.), 890.0(1,4 disub. Benz.Ring) 
653.3(C-Cl).1HNMR(300 MHz, 
CDCl3)10.32(s,1H,tetrazole-NH),5.02(s,2H,CH2),7.00-
8.69(m,19H,ArH).13CNMR(CDCl3)δ:49.6,112.5,113.6,
114.2,124.7,124.1,126.4,128.0,134.1,139.8,142.9,143.7
,FAB-MS, 628.6 
 
[15] (2-{6-Chloro-5-nitro-1-[4-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(4- fluoro -benzylidene)-amine 
Yield:62%, m.p. =217-2210C.Mol.weight 629.04, 
Anal.Calcd for C34H22ClFN8O2: C,64.92; H, 3.53; 
N,17.81 %. IR (KBr): 3528-3115, 2885(C-H str.,CH2), 
1650-1522 (C=N and C=Cstr.), 1549-1360(N-O str., 
NO2), 1189.9 (C-N str.), 892.1(1,4 disub. Benz.Ring) 
648.3(C-Cl).1HNMR(300 MHz, 
CDCl3)10.37(s,1H,tetrazole-NH),5.06(s,2H,CH2),7.05-
8.61(m,19H,ArH).13CNMR(CDCl3)δ: 
59.8,110.7,111.5,112.3,115.4,117.8,120.1,126.1,129.5,
131.3,133.4,136.4,138,140.1,143.7,FAB-MS, 628.8 
 
[16] (2-{6-Chloro-5-nitro-1-[4-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(2-methyl-benzylidene)-amine 
Yield:62%, m.p. =217-2210C.Mol.weight 625.07, 
Anal.Calcd for C35H25ClN8O2: C,67.25; H, 4.03; 
N,17.93 %. IR (KBr): 3520-3133, 2943.6(C-H 
str.,CH3), 2898.8(C-H str.,CH2), 1666-1513 (C=N and 
C=Cstr.), 1540-1333(N-O str., NO2), 1194 (C-N str.), 
887.5(1,4 disub. Benz.Ring) 644.7(C-Cl).1HNMR(300 
MHz, CDCl3)10.56(s,1H,tetrazole-
NH),5.00(s,2H,CH2), 2.21(m,3H,CH3),7.22-
8.51(m,19H,ArH).13CNMR(CDCl3)δ: 
19.4,52.3,112.3,114.1,116.2,117.1, 
118.1,119.2,120.1,123.1,128,144.2,FAB-MS, 624.17 
 
[17] (2-{6-Chloro-5-nitro-1-[4-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(3-methyl-benzylidene)-amine 
Yield:67%, m.p. =232-2350C.Mol.weight 625.07, 
Anal.Calcd for C35H25ClN8O2: C,67.25; H, 4.03; 
N,17.93 %. IR (KBr): 3526-3139, 2949(C-H str.,CH3), 
2890(C-H str.,CH2), 1660-1508 (C=N and C=Cstr.), 
1532-1365(N-O str., NO2), 1188.7 (C-N str.), 
891.3(1,4 disub. Benz.Ring) 645.3(C-Cl).1HNMR(300 
MHz, CDCl3)10.62(s,1H,tetrazole-
NH),5.04(s,2H,CH2), 2.24(m,3H,CH3),7.18-
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8.48(m,19H,ArH).13CNMR(CDCl3)δ: 
18.1,54.2,112.4,113.2,116.1,123.5,129.1,130.6,133.7,1
38.2,142.9,FAB-MS, 625.32 
 
[18] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(2,3-dimethoxy-benzylidene)-amine 
Yield:58%, m.p. =265-2680C.Mol.weight 671.104, 
Anal.Calcd for C35H27ClN8O4: C,64.43; H, 4.06; 
N,16.70%. IR (KBr): 3526-3139,3087, 2973.6(C-H 
str.,CH3), 2883.2(C-H str.,CH2), 1644-1536 (C=N and 
C=Cstr.), 1554-1306(N-O str., NO2), 1199.5 (C-N str.), 
885.2(1,4 disub. Benz.Ring) 652.8(C-Cl).1HNMR(300 
MHz, CDCl3)10.86(s,1H,tetrazole-
NH),4.96(s,2H,CH2), 3.77(m,6H,CH3),7.11-
8.79(m,18H,ArH).13CNMR(CDCl3)δ: 18.1, 
19.8,52.3,112.3,113.1,115.2,123.1,130.4,135.1,138.1,1
41.2,143.2,145,FAB-MS, 670.79 
 
[19] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(3,4-dimethoxy-benzylidene)-amine 
Yield:58%, m.p. =251-2540C.Mol.weight 671.104, 
Anal.Calcd for C35H27ClN8O4: C,64.43; H, 4.06; 
N,16.70%. IR (KBr): 3520-3133,3097, 2970.0(C-H 
str.,CH3), 2899.8(C-H str.,CH2), 1665-1531 (C=N and 
C=Cstr.), 1507-1319(N-O str., NO2), 1194.0(C-N str.), 
888.5(1,4 disub. Benz.Ring) 650.4(C-Cl).1HNMR(300 
MHz, CDCl3)10.82(s,1H,tetrazole-
NH),4.98(s,2H,CH2), 3.75(m,6H,CH3),7.24-
8.76(m,18H,ArH).13CNMR(CDCl3)δ: 18.1, 
19.8,52.3,112.3,113.1,115.2,123.1,130.4,135.1,138.1,1
41.2,143.2,145,FAB-MS, 671.08 
 
[20] (2-{6-Chloro-5-nitro-1-[2-(1H-tetrazol-5-yl) 
biphenyl-4-ylmethyl] 1H benzoimidazol-2-yl}-
phenyl)-(3,4,5-trimethoxy-benzylidene)-amine 
Yield:70%, m.p. =287-2900C.Mol.weight 701.13, 
Anal.Calcd for C37H29ClN8O5: C,63.38; H, 4.16; 
N,15.98%. IR (KBr): 3555-3114,  2991.2(C-H 
str.,CH3), 2894.1(C-H str.,CH2), 1665-1531 (C=N and 
C=Cstr.), 1522-1343(N-O str., NO2), 1187.0(C-N str.), 
890.8(1,4 disub. Benz.Ring) 646.5(C-Cl).1HNMR(300 
MHz, CDCl3)10.95(s,1H,tetrazole-
NH),4.92(s,2H,CH2), 3.79 (m,9H,CH3),7.24-
8.76(m,17H,ArH).13CNMR(CDCl3)δ: 
14.5,18.1,19.8,52.3,112.7,114.5,116.1,119.1,123.1,136.
2,139.1,142.1,143.6,146.8,FAB-MS, 701.54 
Antihypertensive Activity  
Invasive Method (Direct Method) [13-16]  
Male albino wistar (160-250 gm) rats were used and 
housed at 26±10C room temperature. The rats were 
anaesthetized with sodium chloride 0.9% solution, 
Drug solution 10-μg/100ml, and Heparin 500 
I.U.solution urethane hydrochloride 50% w/v solution 
80 mg/kg i.p. To set up the instrument firstly the level 
of mercury in the left arm of manometer was adjusted 
to 90-100 mm of Hg (normal blood pressure of 
rat).this was done in steps of 10mm at a time and the 
physiogram so obtained was used as calibration graph 
for calculations. The Jugular vein and carotid artery 
were surgically cannulated for drug administration for 
recording the blood pressure respectively. The trachea 
was cannulated in order to provide artificial 
respiration to rat during the experiment. By means of 
three way stop cock and a stainless steel needle at the 
end of P.E. tubing was attached to arterial cannula for 
B.P., Transducers and the Venus cannula to a syringe. 
Then both the cannulas were filled by heparinized 
saline before the administration. Arterial cannula was 
connected via transducer to physiograph recorder. 
Several baseline readings of systolic and diastolic 
pressures were recorded. The physiograph shows the 
reduction of the blood pressure with compare to 
losratan. Synthesized compounds were screened in 
presence of Angiotensin II induced hypertension (0.5 
μg/kg i.v.). Observations are given in the table 1, 2. 
 
Results and discussion 
All the synthesized benzimidazole incorporated 
antihypertensive activity with standard drug 
compared all synthesized compounds [synthesis 
compounds 1-20]. Almost all the newly synthesized 
substituted 6-Chloro-5-nitro-benzimidazole showed 
good antihypertensive activity with the goal of 
investigating the structure–activity relationships of 
benzimidazole, based molecules, fifteen analogs 
compounds were synthesized (Figure 2). Synthesis 
has been carried out of selected benzimidazole 
derivatives having electron donor and acceptor 
substituents at 5-position nitro group and 2-postions 
different aryl groups and their authencity and purity 
have been established through appropriate spectral 
and chromatographic techniques.  
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Table 1. Blood pressure values for synthesized compounds over duration of 90 minutes 
 
                                           Mean Arterial Pressure After Comp. 
No.  0 
min. 
10 
min. 
20 
min. 
30 
min. 
40 
min. 
50 
min. 
60 
min. 
70 
min. 
80 
min. 
90 
min. 
Losartan 172 169 161 154 148 140 136 128 119 113 
1 177 170 167 161 156 148 143 138 130 124 
2 178 172 166 159 151 144 137 130 125 120 
3 174 166 162 156 148 141 138 131 126 122 
4 173 168 159 148 142 135 129 122 117 110 
5 180 176 170 166 161 154 148 141 136 130 
6 177 171 167 159 151 145 138 128 119 108 
7 170 166 160 154 148 140 133 124 119 112 
8 181 177 170 162 153 147 138 130 126 120 
9 175 170 164 156 150 143 138 130 124 118 
10 175 169 162 157 150 144 135 126 121 116 
11 174 170 161 152 144 139 135 129 124 117 
12 177 170 164 157 149 140 131 122 116 109 
13 176 170 164 158 151 144 138 130 122 112 
14 181 176 170 165 159 151 143 137 130 122 
15 174 168 160 155 149 141 134 129 125 119 
16 184 175 168 162 156 150 145 139 133 128 
17 178 173 167 159 150 143 136 127 120 114 
18 176 170 165 158 153 147 139 131 126 120 
19 179 174 168 160 154 145 140 131 123 116 
20 181 177 170 164 157 151 145 136 125 118 
 
 
The synthesized compounds were characterized on 
the basis of chemical and spectral data. Synthetic 
scheme for target compounds was divided into two 
steps. Step I involved synthesis of different aryl 
aldehydes substituents benzimidazoles by 
condensation reaction of o-phenylenediamine with 
the respective anthranilic acid then corresponding 
react with PPA 170-172oC and react with 5-postion 
nitro group with biphenyl tetrazole . Our initial efforts 
of optimizing the benzimidazole structures were 
focused on either replacing the 2-substituted 5-nitro 
groups on different substituents at different positions 
of the benzimidazole derivatives. We recently 
determined the significance of the 5 position of the 
benzimidazole ring for inhibitory activity. We also 
investigated the possible effect of any change in the 
linker between both aromatic rings upon the 
bioactivity. The structures of the synthesized 
compounds were confirmed using IR, NMR and 
elemental analysis methods. The higher activity of 4- 
 
 
chloro-5-nitro-benzimidazole derivatives may be 
ascribed to the ability of nitro group to act as H-bond 
acceptor with respect to the receptor site. Moreover, 
the bulk of nitro group may optimally “fill up” the 
receptor pocket and hence results in closer proximity 
to the interacting surface of the receptor. It may 
consequently increase their affinity to the receptor 
site. The present work was mainly intended to 
establish the moieties which are responsible for 
Angiotension-II inhibition. Presence of Nitro group 
has increased the activity substantially over the 
substituted one [1] to [20]. The maximum activity has 
been observed with nitro group (Compound 4, 6, 7, 
12, 13, 17) [Table 1 and 2]. Biological activity of 
synthesized compounds was carried out using rat 
blood pressure measurement experiment; the 
maximum fall blood pressure produced by standard 
drug compare with our synthesis molecule Losartan is 
from value 172mm Hg to 113 mm Hg over a period 
90 minutes.  
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Table 2. Antihypertensive activity of synthesized 
compounds. 
 
Compound. No Minimum Blood 
pressure 
value(mm Hg) 
Duration of 
hypertension 
effect(min.) 
Losratan 113 90 
1 117 100 
2 114 105 
3 116 100 
4 110 90 
5 115 110 
6 108 90 
7 112 90 
8 114 100 
9 112 95 
10 110 95 
11 113 95 
12 109 90 
13 112 90 
14 116 100 
15 113 95 
16 118 105 
17 114 90 
18 115 95 
19 110 98 
20 115 95 
 
Conclusion 
Different aryl groups reaction with Substituted 4-
chloro-5-nitro-benzimidazole derivatives nucleus 
coupled to tetrazole biphenyl group have been 
designed synthesized and evaluated for angiotensin II 
antagonism. Compound with nitro group at 5-position 
and aryl groups chain at 2- position have been found 
to be less potent than standard drug. Additionally a 
novel and simple method for synthesis of tetrazole 
biphenyl moiety has been devised to improve safety 
and yield. 
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